Global Insulin Market, By Product Type (Intermediate Acting Insulin, Short Acting Insulin, Rapid Acting Insulin, Long Acting Insulin), Source (Human Recombinant Insulin, Insulin Analogs), Disease Type (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes, Prediabetes), Delivery Devices (Syringes, Pens, Pumps, Others), End Users (Home Healthcare, Hospitals, Over The Counter (OTC), Clinics, Others) – Industry Trends and Forecast to 2029.
Insulin Market Analysis and Size
Pancreatic islets of Langerhans release insulin, a peptide hormone with 51 amino acids. By attaching to receptors on the plasma membranes of the cells, insulin helps to normalize the absorption of glucose in the circulation and control blood glucose levels. Depending on how long it takes for an effect, three forms of insulin are classified: short-acting, intermediate-acting, and long-acting insulin. In hospitals, insulin is frequently administered intravenously, subcutaneously, and intramuscularly to treat hyperglycemia.
Data Bridge Market Research analyses that the insulin market which was USD 18.5 billion in 2021, would rocket up to USD 25.12 billion by 2029, and is expected to undergo a CAGR of 3.90% during the forecast period 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Insulin Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product Type (Intermediate Acting Insulin, Short Acting Insulin, Rapid Acting Insulin, Long Acting Insulin), Source (Human Recombinant Insulin, Insulin Analogs), Disease Type (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes, Prediabetes), Delivery Devices (Syringes, Pens, Pumps, Others), End Users (Home Healthcare, Hospitals, Over The Counter (OTC), Clinics, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Sanofi (France), Novo Nordisk A/S (Denmark), Eli Lilly and Company (U.S.), Biocon Ltd. (India), Julphar (UAE), Ypsomed AG (Switzerland), BD (U.S.), Wockhardt Ltd. (India), B. Braun Melsungen AG (Switzerland), and Biodel Inc. (U.S.), Shanghai Fosun Pharmaceutical Co., Ltd (China), Tonghua Dongbao (China)
|
|
Market Opportunities
|
|
Market Definition
The human pancreas secretes the hormone insulin, which regulates the body's metabolism of lipids, proteins, and carbohydrates as well as blood glucose (sugar) levels. Different insulin strengths are available; the most popular is U-100, which is used as a supplement to diet and exercise to improve glycemic control in both children and adults.
Insulin Market Dynamics
Drivers
- Rise in demand of insulin
The market for human insulin is expected to expand during the forecast period as a result of factors including an expanding diabetes patient population, rising population exposure to major diabetes risk factors, rising market demand for human insulin analogues, technological developments in the field of human insulin delivery devices, and favourable medical reimbursements.
- Rising number of diabetic patients
Increased numbers of diabetic patients, rising rates of obesity among the elderly population, growing public awareness of the advantages of insulin, and government initiatives to improve healthcare are some of the factors that are predicted to boost the growth of the insulin market in the forecast period of 2022–2029.
- Rise in patient population
On the other hand, a rising patient population with diabetes and an increase in the number of development activities pertaining to insulin delivery systems will further encourage a number of opportunities that will contribute to the expansion of the insulin market during the forecast period.
Opportunities
- Increase in the number of research and development activities
Additionally, R&D efforts in the insulin market are increasing as scientists worldwide work to create a superior insulin molecule for diabetic patients that boosts effectiveness and reduces negative effects.
Restraints/Challenges
On the other hand, stringent regulatory requirements for product approval, increasing insulin cost, lack of favourable insurance policies, and rising competition among the existing manufacturers will obstruct the market's growth rate.
This insulin market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the insulin market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Insulin Market
The COVID-19 epidemic had an positive impact on the companies' sales. Lockdowns arising from the COVID-19 epidemic forced people to put off getting their health checked, reducing the amount of tests performed and reagent sales. However, as governments gradually loosen travel restrictions, there is a rebound in testing numbers. With the COVID-19 pandemic, dealing with infectious diseases has become a major medical concern around the world. In addition to vaccinations and therapeutic medications, there is an increasing demand for more precise and simple testing technologies as well as the expansion of testing structures.
Recent Development
- In October 2019 , Semglee's formal launch was announced by Mylan N.V., a multinational generic and speciality pharmaceuticals firm, and Biocon Ltd., an innovation-led, fully integrated biopharmaceutical company. It is a prescription insulin used to manage excessive blood sugar in both type 1 and type 2 diabetic children and adults.
- In June 2019 , The producer of the wearable, prescription-only insulin administration system V-Go, Valeritas Holdings, Inc., said that it had submitted a "510(k) Device Modification" filing to the FDA to include the use of regular human insulin (RHI) in V-Go.
Global Insulin Market Scope
The insulin market is segmented on the basis of product type, source, delivery process, disease type, and end users. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product Type
- Intermediate Acting Insulin
- Short Acting Insulin
- Rapid Acting Insulin
- Long Acting Insulin
Source
- Human Recombinant Insulin
- Insulin Analogs
Disease Type
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes
- Prediabetes
Delivery Devices
- Syringes
- Pens
- Pumps
- Others
End Users
- Home Healthcare
- Hospitals
- Over The Counter (OTC)
- Clinics
- Others
Insulin Market Regional Analysis/Insights
The insulin market is analysed and market size insights and trends are provided by country, product type, source, delivery process, disease type, and end users as referenced above.
The countries covered in the insulin market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the insulin market due to the high prevalence of diabetes patients along with rising research activities in the region and provision of various manufacturers.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2022 to 2029 due to the growing geriatric population along with rising occurrences of diabetes among the growing population, rising awareness among the people regarding the benefits of insulin and surging levels of investment for the development of advanced and technical product.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Insulin Market Share Analysis
The insulin market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to insulin market.
Some of the major players operating in the insulin market are:
- Sanofi (France)
- Novo Nordisk A/S (Denmark)
- Eli Lilly and Company (U.S.)
- Biocon Ltd. (India)
- Julphar (U.A.E.)
- Ypsomed AG (Switzerland)
- BD (U.S.)
- Wockhardt Ltd. (India)
- B. Braun Melsungen AG (Switzerland)
- Biodel Inc. (U.S.)
- Shanghai Fosun Pharmaceutical Co., Ltd (China)
- Tonghua Dongbao (China)
SKU-